<?xml version="1.0" encoding="UTF-8"?>
<document id="DDI-DrugBank.d532">
    <sentence id="DDI-DrugBank.d532.s0" text="Formal drug interaction studies with Abciximab have not been conducted.">
        <entity id="DDI-DrugBank.d532.s0.e0" charOffset="37-45"
            type="drug" text="Abciximab"/>
    </sentence>
    <sentence id="DDI-DrugBank.d532.s1" text="Abciximab has been administered to patients with ischemic heart disease treated concomitantly with a broad range of medications used in the treatment of angina myocardial infarction and hypertension.">
        <entity id="DDI-DrugBank.d532.s1.e0" charOffset="0-8"
            type="drug" text="Abciximab"/>
    </sentence>
    <sentence id="DDI-DrugBank.d532.s2" text="These medications have included heparin, warfarin, beta-adrenergic receptor blockers, calcium channel antagonists, angiotensin converting enzyme inhibitors, intravenous and oral nitrates, ticlopidine, and aspirin.">
        <entity id="DDI-DrugBank.d532.s2.e0" charOffset="32-38"
            type="drug" text="heparin"/>
        <entity id="DDI-DrugBank.d532.s2.e1" charOffset="41-48"
            type="drug" text="warfarin"/>
        <entity id="DDI-DrugBank.d532.s2.e2" charOffset="51-83"
            type="group" text="beta-adrenergic receptor blockers"/>
        <entity id="DDI-DrugBank.d532.s2.e3" charOffset="86-112"
            type="group" text="calcium channel antagonists"/>
        <entity id="DDI-DrugBank.d532.s2.e4" charOffset="115-154"
            type="group" text="angiotensin converting enzyme inhibitors"/>
        <entity id="DDI-DrugBank.d532.s2.e5" charOffset="178-185"
            type="group" text="nitrates"/>
        <entity id="DDI-DrugBank.d532.s2.e6" charOffset="188-198"
            type="drug" text="ticlopidine"/>
        <entity id="DDI-DrugBank.d532.s2.e7" charOffset="205-211"
            type="brand" text="aspirin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d532.s3" text="Heparin, other anticoagulants, thrombolytics, and anti platelet agents are associated with an increase in bleeding.">
        <entity id="DDI-DrugBank.d532.s3.e0" charOffset="0-6"
            type="drug" text="Heparin"/>
        <entity id="DDI-DrugBank.d532.s3.e1" charOffset="15-28"
            type="group" text="anticoagulants"/>
        <entity id="DDI-DrugBank.d532.s3.e2" charOffset="31-43"
            type="group" text="thrombolytics"/>
        <entity id="DDI-DrugBank.d532.s3.e3" charOffset="50-69"
            type="group" text="anti platelet agents"/>
    </sentence>
    <sentence id="DDI-DrugBank.d532.s4" text="Patients with HACA titers may have allergic or hypersensitivity reactions when treated with other diagnostic or therapeutic monoclonal antibodies.">
        <entity id="DDI-DrugBank.d532.s4.e0" charOffset="98-107;124-144"
            type="group" text="diagnostic monoclonal antibodies"/>
        <entity id="DDI-DrugBank.d532.s4.e1" charOffset="112-144"
            type="group" text="therapeutic monoclonal antibodies"/>
    </sentence>
</document>
